A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.

ABSTRACT: Primary objectives: Non Progression rate at 6 months Primary endpoints: The primary endpoint non progression rate will be presented by the percentage of patients without progression at 6 months with the 95% confidence interval.

DISEASE(S): Refractory Wtkras Metastatic Colorectal Cancer,Metastatic Colorectal Cancer

PROVIDER: 2530498 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR